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Metabolic homeostasis requires that cellular energy levels are adapted to environmental cues. This adapta-
tion is largely regulated at the transcriptional level, through the interaction between transcription factors, cor-
egulators, and the basal transcriptional machinery. Coregulators, which function as both metabolic sensors
and transcriptional effectors, are ideally positioned to synchronize metabolic pathways to environmental
stimuli. The balance between inhibitory actions of corepressors and stimulatory effects of coactivators
enables the fine-tuning of metabolic processes. This tight regulation opens therapeutic opportunities to
manage metabolic dysfunction by directing the activity of cofactors toward specific transcription factors,
pathways, or cells/tissues, thereby restoring whole-body metabolic homeostasis.Introduction
Metabolic programs that synchronize energy homeostasis with
external cues are often regulated at the transcriptional level.
Transcription factors, and particularly many nuclear receptors,
are keymediators in these control circuits, as they can transduce
environmental signals and directly influence gene expression
(Chawla et al., 2001; Francis et al., 2003). Transcriptional coregu-
lators have emerged as equally important, as it is the delicate
balance between the inhibitory actions of corepressors and the
stimulatory effects of coactivators on transcription that fine-
tunes many homeostatic processes (Feige and Auwerx, 2007;
Rosenfeld et al., 2006).
Among many coregulators with metabolic roles, studies of the
peroxisome proliferator-activated receptor (PPAR) coactivator
1a (PGC-1a) (Fernandez-Marcos and Auwerx, 2011; Gupta
et al., 2011) and sirtuin 1 (SIRT1) (reviewed by Bordone and
Guarente, 2005; Canto´ and Auwerx, 2012; Haigis and Sinclair,
2010; Houtkooper et al., 2012) have been formative for the field.
PGC-1a is highly expressed in mitochondria-rich tissues such as
brown adipose tissue (BAT) and cardiac and skeletal muscles. In
conjunction with a small set of transcription factors, it controls
mitochondrial functions, such as oxidative phosphorylation and
mitochondrial biogenesis, through the regulation of large clus-
ters of genes (Fernandez-Marcos and Auwerx, 2011; Gupta
et al., 2011; Scarpulla, 2006). SIRT1 is the best-characterized
member of the sirtuin family of NAD+-dependent deacetylases,
named after the Saccharomyces cerevisiae gene silent informa-
tion regulator 2 (Sir2p) (reviewed by Canto´ and Auwerx, 2012;
Haigis and Guarente, 2006; Houtkooper et al., 2012). Most of
the metabolic actions of SIRT1, which involve the deacetylation
and activation of transcription regulators (such as PGC-1a), also
affect mitochondrial function (Canto´ et al., 2009, 2010; Rodgers
et al., 2005) and may as such contribute to the beneficial effects
of caloric restriction on lifespan (Canto´ and Auwerx, 2012).
The extensive body of literature on PGC-1a and SIRT1, which
illustrates a pleiotropic impact of these cofactors on almost
all aspects of metabolism, has increased awareness of this26 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.additional layer of physiological regulation and incited re-
searchers to define the metabolic roles of cofactors. In this re-
view, we will provide examples of the regulatory roles played
by other cofactors in homeostasis and physiology (Figure 1).
Furthermore, we will illustrate how multiple signaling pathways
impact the activity of such cofactors. Together, the evidence dis-
cussed in this review supports the concept of coregulators fine-
tuning transcriptional control of metabolism.
Selected Coregulators and the Control of Metabolism
NCoA1, NCoA2, and NCoA3
The three members of the nuclear receptor coactivator (NCoA,
also known as SRC for steroid receptor coactivator) family
were among the first coregulators cloned (Halachmi et al.,
1994), based upon their ligand-dependent recruitment to nuclear
receptors, which wasmediated by the three a-helical LXXLLmo-
tifs within their sequence (Chen et al., 1997; On˜ate et al., 1995;
Voegel et al., 1996). Although the molecular underpinning of
the interaction of the NCoA coactivators with nuclear receptors
was defined early, the first indication of a metabolic role for the
NCoA family came much later with the observation that mice
with a germline mutation of NCoA2 (SRC2/TIF2/GRIP1) are pro-
tected against obesity when fed a high-fat diet (HFD) (Picard
et al., 2002). In wild-typemice, a HFD inducesNCoA2 expression
in WAT, and NCoA2 expression favors adipocyte differentiation
in vitro (Louet et al., 2006; Picard et al., 2002), indicating that
NCoA2 may play a role in fat storage, likely by coactivating
PPARg. Consistent with an important role in adipose tissue,
the NCoA2/ mice displayed reduced fatty acid uptake and
storage and increased lipolysis in white adipose tissue (WAT)
and enhanced adaptive thermogenesis in BAT (Picard et al.,
2002). NCoA2 also plays multiple roles in the liver, where expres-
sion of genes required for fatty acid synthesis, such as Fasn, is
reduced in the livers of germline NCoA2/ mice (Jeong et al.,
2006). Notably, NCoA2 deficiency mimics von Gierke’s disease
(Chopra et al., 2008), a rare metabolic disease that typically
results from inactivation of the glucose-6-phosphatase (G6PC)
Figure 1. Metabolic Coregulator Protein Families
A representative domain structure of the Pfam-annotated domains is shown for eachmajor protein family discussed in this review. Each color corresponds to one
protein family, and differences in shading indicate distinct domains within the same structure. Domain structures are based on the human protein. HLH, basic
helix-loop-helix; PAS, Per, Arnt, Sim domain; SRC1, steroid receptor coactivator; Nuc Rec Co-act, nuclear receptor coactivator; SANT, SANT (Swi3, Ada2, N-
CoR, and TFIIIB) domain, which contains the DAD or deacetylase activating domain; RID, nuclear receptor interaction domain; RD, repressive domain; PCAF N,
PCAF (P300/CBP-associated factor) N-terminal domain; Acetyl transf, acetyltransferase; Hist deacetyl, histone deacetylase; HDAC4 Gln, glutamine-rich
N-terminal domain of histone deacetylase 4; Arb2, Arb2 domain; TORC N, transducer of regulated CREB activity, N terminus; TORC M, transducer of regulated
CREB activity, middle domain; TORC C, transducer of regulated CREB activity, C terminus; TFIIB, transcription factor TFIIB repeat; RB A, retinoblastoma-
associated protein A domain; RB B, retinoblastoma-associated protein B domain; RB C, Rb C-terminal domain; MED1, mediator of RNA polymerase II tran-
scription subunit 1; CPD1, Cdc4 phosphodegron 1; CPD2, Cdc4 phosphodegron 2; DAC, deacetylase catalytic domain.
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glucose by the liver (Lei et al., 1996).
The related coactivator NCoA3 (SRC3/p/CIP/AIB-1/ACTR) is
equally important for energy homeostasis. In fact, like NCoA2/
mice, upon high-fat feeding, germline or full-body NCoA3/
mice remain lean and metabolically fit, as defined by insulin
sensitization, low lipid levels, cold tolerance, and exercise endur-
ance (Coste et al., 2008). Although reduced adipocyte differenti-
ation via alteration in PPARg-dependent gene transcription may
contribute to this effect (Louet et al., 2006), the robust mitochon-
drial activation in BAT and skeletal muscle, as a consequence of
PGC-1a deacetylation and activation, may explain the lion’s
share of this phenotype (Coste et al., 2008). NCoA3 stimulates
the expression of K (lysine) acetyl transferase 2A (KAT2A, also
known as GCN5), the only known PGC-1a acetyl transferase
(Lerin et al., 2006), which inhibits PGC-1a function. This oxidative
phenotype observed in germline NCoA3/ mice (Coste et al.,2008) was later confirmed in muscle-specific NCoA3skm/
mice (Duteil et al., 2010). As is the case for NCoA2, NCoA3 defi-
ciency also mimics a rare disease, i.e., solute carrier family 25
(carnitine/acylcarnitine translocase), member 20 (SLC25A20)
deficiency (York et al., 2012), with its myriad of phenotypes,
including hypoglycemia, impaired neurological functions, and
myopathy (Rubio-Gozalbo et al., 2004).
Unlike NCoA2 and NCoA3, the thirdmember of the NCoA fam-
ily, NCoA1, in conjunction with PGC-1a, appears to orient
PPARg activity toward an oxidative program, protecting against
obesity and type 2 diabetes mellitus (T2DM) in mice. Indeed,
NCoA1/ mice are fatter than littermate controls (Picard et al.,
2002), and PGC-1a relies heavily on its interaction with NCoA1
for its activation (Puigserver et al., 1999). The fact that selective
recruitment of NCoA1 (and PGC-1a), instead of its family mem-
bers NCoA2 (Picard et al., 2002; Puigserver et al., 1999) or
NCoA3 (Coste et al., 2008; Duteil et al., 2010), has suchCell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 27
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Figure 2. Tissue-Specific Roles of NCoR1
(A) NCoR1 depletion in WAT enhances the activity of the unphosphorylated form of PPARg, which enhances adipogenesis and insulin sensitivity and reduces
inflammation. In 3T3-L1 preadipocytes, the ubiquitin ligase Siah2 targets NCoR1 for proteasomal degradation, promoting the expression of CREB-dependent
mitochondrial genes.
(B) In muscle, NCoR1 activity is reduced under conditions in which fatty acid oxidation (FAO) is required. Genetic deletion of NCoR1 in the skeletal muscle
enhances exercise endurance through the dereperession of PPARb/PPARd, ERRs, and MEF2.
(C) mTORC1 activation in liver during feeding modifies the interaction of S6K2 with NCoR1 and promotes its relocalization in the nucleus, leading to the silencing
of the ketogenic target genes of PPARa. Specific genetic disruption of the NCoR1-HDAC3 interaction results in alterations in diurnal gene expression controlled
by REV-ERB.
(D) Macrophage-specific NCoR1 mutation reduces inflammation through a selective derepression of the liver X receptor (LXR).
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(SPRMs) that favor NCoA1 and PGC-1a recruitment to PPARg. A
first case in point was the compound Fmoc-L-Leu, which
changes PPARg conformation such that it selectively recruits
NCoA1, resulting in insulin sensitization without the induction
of weight gain commonly associated with PPARg activation
(Rocchi et al., 2001).
NCoR1/SMRT and RIP140
Two critical repressors of a number of different nuclear receptors
are the nuclear receptor corepressor (NCoR1) and the silencing
mediator for retinoid and thyroid hormone receptor (SMRT, also
known as NCoR2). Only recently have studies utilizing tissue-
specific deletions begun to elucidate the in vivo roles of
NCoR1 and SMRT because germline NCoR1/ and SMRT/
mice are embryonic lethal (Jepsen et al., 2000, 2007). These
studies have been complemented by analysis of micewith subtle
mutations in different domains of SMRT and NCoR1, such as the
SMRTRID, SMRTRID1, liver-specific NCoRi, L-NCoRDID, NCoR-
DID, and NCoR1mDAD mice (reviewed by Mottis et al., 2013).
Analysis of these mice indicated that derepression of the activity
of several nuclear receptors was a common feature of NCoR1/
SMRT loss of function, as illustrated by the activation of the thy-
roid receptor (Astapova et al., 2008, 2011; Feng et al., 2011),
activation of PPARg causing enhanced adipogenesis (Fang
et al., 2011; Nofsinger et al., 2008; Reilly et al., 2010; You
et al., 2013), and alterations in diurnal gene expression patterns
controlled by Rev-Erba (Alenghat et al., 2008) (Figure 2).
In line with this premise, the phenotype of the WAT-specific
NCoR1 knockout mouse (NCoR1ad/) reflects PPARg dere-
pression, which causes weight gain and increased adipogene-
sis, with an accumulation of active smaller adipocytes, in
contrast to the adipocyte hypertrophy typical of obesity (Li
et al., 2011). Glucose tolerance and insulin sensitivity are28 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.improved, and WAT macrophage infiltration is attenuated in
NCoR1ad/ mice. Furthermore, thiazolidinediones, a class of
specific PPARg agonists, failed to improve insulin sensitivity in
the NCoR1ad/ mice, reflecting maximal derepression or acti-
vation of PPARg. CDK5 was previously shown to phosphorylate
PPARg and inhibit its activity, promoting insulin resistance (Choi
et al., 2010). Notably, NCoR1 depletion in WAT causes enrich-
ment in the unphosphorylated form of PPARg, which has in-
sulin-sensitizing actions, suggesting that NCoR1 facilitates
phosphorylation of PPARg by CDK5 (Figure 2A).
The increased exercise endurance of mice with a specific
NCoR1 deletion in the skeletal muscle (NCoR1skm/) also con-
curs with the idea of general transcriptional derepression (Yama-
moto et al., 2011). Themuscle fiber type shift and the induction of
oxidative metabolism in NCoR1skm/ mice is the consequence
of its repressive interactions with PPARb/PPARd and/or ERRs (a
and g) (Pe´rez -Schindler et al., 2012; Yamamoto et al., 2011),
though the interaction of NCoR1 with myocyte enhancer factor
2 (MEF2), a transcriptional regulator of muscle development
and remodeling, may also be involved (Figure 2B). Interestingly,
NCoR1 activity also appears to be regulated dynamically in the
muscle, as its expression and/or nuclear localization was
reduced in conditions where fatty acid oxidation was activated,
such as in long-term fasting, high-fat feeding, and endurance ex-
ercise (Yamamoto et al., 2011). Of relevance to the role of NCoR1
in oxidative muscle metabolism was the recent identification of
NCoR1 as a generalized repressor of mitochondrial activity in a
genome-wide study mapping nuclear protein degradation (Catic
et al., 2013) (Figure 2A).
In the liver of aged mice, NCoR1 is thought to repress PPARa,
the main transcriptional activator of ketogenesis. PPARa
signaling was attenuated, and fasting-induced ketogenesis
was blunted in mice with hyperactive mammalian target of
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2010) (Figure 2C). mTORC1 mediated this effect, at least in
part, through increasing the nuclear localization of NCoR1.
This effect has been attributed to the downstream target of
mTORC1, S6 kinase 2 (S6K2), which interacts with and controls
the subcellular localization of NCoR1, the predominant core-
pressor of PPARa (Kim et al., 2012; Sengupta et al., 2010). In
line with this, S6K2 was found to associate with NCoR1 in nuclei
of ob/ob hepatocytes, confirming a direct effect of energy avail-
ability andmTORC1 signaling on NCoR1 intracellular localization
(Kim et al., 2012). Further work is required to establish the exact
impact of NCoR1 in the liver, as both these studies (Kim et al.,
2012; Sengupta et al., 2010) appear to contradict a recent report
showing that hepatic NCoR1 deletion results in hepatosteatosis
(Sun et al., 2013).
It is striking that the phenotypes caused by attenuated
NCoR1/SMRT signaling in muscle, liver, and fat, e.g., oxidative
muscle metabolism, enhanced ketogenesis, and reduced fat
cell size, are all reflective of unopposed PGC-1a activity, high-
lighting the potential antagonism between corepressors and co-
activators on a physiological level. Furthermore, these studies
also suggest that inhibiting mTORC1 actions (Kim et al., 2012;
Sengupta et al., 2010) and/or insulin signaling (Yamamoto
et al., 2011) will attenuate NCoR1 corepressor signaling and alter
metabolic homeostasis, providing a molecular mechanism by
which insulin and other hormones signaling to mTOR will result
in enhanced transcriptional repression of specific nuclear recep-
tor target genes.
One more striking phenotype was observed in mice with a
macrophage-specific NCoR1 mutation. Although one could
expect that a macrophage NCoR1 deletion would be proinflam-
matory due to the derepression of the inflammatory response,
inflammation was paradoxically attenuated (Li et al., 2013)
(Figure 2D). This phenotype was in part explained by the selec-
tive derepression of the liver X receptor (LXR), which leads to
the induction of several lipogenic genes that drive the production
of anti-inflammatory fatty acids (e.g., palmitoleic acid and u3
fatty acids) within macrophages that inhibit NF-kB-dependent
inflammatory pathways (Li et al., 2013).
Another important consideration for all studies of NCoR1 and
SMRT function is that they appear to form an obligate complex
with the class I histone deacetylase HDAC3. A combination of
elegant genetic studies, using a knockin mouse model in which
the deacetylase activation domains (DAD, contained within the
SANT) of both NCoR1 and SMRT were incapacitated for
HDAC3 interaction (You et al., 2013) and liver-specific NCoR1
and SMRT loss-of-function mouse models (Sun et al., 2013),
with pharmacological studies with HDAC inhibitors (Sun et al.,
2013), confirmed the suggestive biochemistry that these pro-
teins (NCoR1 in particular) are required for a significant part of
the activity of HDAC3. Furthermore, these studies also indicated
that HDACs have nonenzymatic roles in transcriptional regula-
tion, which are not affected by HDAC inhibitors (Sun et al., 2013).
Finally, another broad-acting repressor of nuclear receptors,
which is unrelated in sequence to NCoR1/SMRT, is the nuclear
receptor interacting protein 1 (NRIP1 or RIP140), which functions
as a corepressor for several nuclear receptors, such as the
PPARs and ERRs (Debevec et al., 2007). Genetic ablation of
theNrip1 gene increasesmitochondrial biogenesis and oxidativemetabolism in muscle (Seth et al., 2007) and adipose tissue
(Debevec et al., 2007) and protects mice against metabolic
dysfunction (Leonardsson et al., 2004; Powelka et al., 2006).
KAT2A(GCN5) and KAT2B(pCAF)
KAT2A (GCN5) was discovered and purified based on its his-
tone acetyltransferase activity from the ciliate Tetrahymena
termophila (Brownell and Allis, 1995; Brownell et al., 1996).
The homology of this protein to the putative yeast transcrip-
tional coactivator Gcn5 provided the first basis of an intimate
link between histone acetylation and transcriptional activation.
Histone acetylation allows the relaxation of chromatin, facili-
tating access of transcription factors to DNA to initiate tran-
scription (Kouzarides, 2000; Shogren-Knaak and Peterson,
2006). Since this discovery, several other histone acetyltrans-
ferases (HATs) were identified and divided into five subclasses
(Roth et al., 2001): the GCN5-related N-acetyltransferases
(GNATs), the MYST-related HATs (MOZ, Ybf2/Sas3, Sas2 and
Tip60), the p300/CREB binding protein (CBP) HATs, the general
transcription factor HATs (which include the TFIID subunit TBP-
associated factor-1 [TAF1]), and the nuclear hormone-related
HATs, NCoA1–NCoA3 (discussed above).
Whereas KAT2Awas initially studied for its role in histone acet-
ylation and locus-specific coactivator functions, it also functions
as a simple acetyltransferase for a wide range of transcriptions
factors (Bannister and Miska, 2000), including PGC-1a (Lerin
et al., 2006) and PGC-1b (Kelly et al., 2009). Although other ace-
tyltransferases, such as p300, NCoA1, and NCoA3, were shown
to interact with PGC-1a, only KAT2A was able to acetylate and
inhibit PGC-1a in vivo and in vitro, leading (among other effects)
to the attenuation of PGC-1a-induced gluconeogenesis (Lerin
et al., 2006). Moreover, NCoA3 facilitated the acetylation and
inactivation of PGC-1a through its effect on the expression of
KAT2A (Coste et al., 2008). Notably, the expression of both
NCoA3 and KAT2A is reduced upon fasting, whereas it is
induced by HFD, which is exactly the mirror image of the expres-
sion of the deacetylase SIRT1, which is induced and reduced by
the same conditions (Coste et al., 2008). This coordinated
change in expression of NCoA3, KAT2A, and SIRT1 will subse-
quently, through its consorted effect on PGC-1a (becoming de-
acetylated and active when energy is limiting and acetylated and
inactive when energy is abundant) affect PGC-1a-mediated en-
ergy expenditure and synchronize energy expenditure with en-
ergy needs (Coste et al., 2008) (Figure 3). In a further twist to
this story, SIRT6 has recently been shown to associate with
and deacetylate KAT2A (Dominy et al., 2012). The SIRT6-medi-
ated KAT2A deacetylation in turn changes the phosphorylation
state of KAT2A, ultimately enhancing its KAT activity toward
PGC-1a. In the liver, this SIRT6/ KAT2A/ PGC-1a signaling
pathway reduces PGC-1a activity, attenuates the expression of
gluconeogenic genes, and dampens hepatic glucose output, an
observation that can have important therapeutic implications for
the management of diabetes (Dominy et al., 2012).
While the role of KAT2A has been best established in the
context of the coregulator PGC-1a, there is much to be learned
concerningwhich promoters aremost regulated through KAT2A/
KAT2B-dependent mechanisms, as opposed to p300/CBP- or
other HAT-dependent mechanisms. A recent study found that
while KAT2A/KAT2B correlated with H3K9 acetylation on an
endogenous PPARb/PPARd target in response to ligandCell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 29
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Figure 3. Energy Levels Control AMPK, PKA, SIRT1, and PGC-1a to
Govern Mitochondrial Metabolism
In times of energy depletion, such as during caloric restriction or exercise,
energy stress is sensed and transduced by the AMP-activated kinase (AMPK).
AMPK activation promotes an increase in NAD+ levels, leading to the activation
of the SIRT1 deacetylase, which in turn deacetylates and activates PGC-1a.
PGC-1a enhances the expression of genes involved in mitochondrial meta-
bolism, thus improving mitochondrial function. On the other hand, calorie-rich
diets or situations in which energy is oversupplied promote the expression of
NCoA3, which positively regulates the protein levels of the acetyltransferase
KATA2A, which acetylates and decreases the transcriptional activity of PGC-
1a. In thismetabolic network, the enzyme ATP citrate lyase (ACLY) provides the
acetyl-CoA required for the enzymatic reaction of acetylation. Finally, stimula-
tion of cAMP/PKA signaling, as seen after epinephrine and glucagon release,
enhances the expression of Sirt1 and the phosphorylation of SIRT1, reinforcing
its deacetylase activity to ultimately promote PGC-1a deacetylation.
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activation, unlike p300/CBP (Jin et al., 2011). In contrast, how-
ever, another study found that p300/CBP recruitment to
CREB-dependent targets was dispensable for cyclic AMP
(cAMP)-induced gene expression, which relied more heavily on
non-HAT coactivators from the CRTC family (Kasper et al.,
2010).
The contribution of HATs in cAMP-dependent transcription in
liver was, however, underscored in a recent study finding that
KAT2B (PCAF) mediates the increase in H3K9 acetylation seen
at promoters of gluconeogenic genes under conditions where
their expression is elevated, including fasting and in diabetic
models (Ravnskjaer et al., 2013).
Collectively, much work is still needed to determine which sets
of promoters are predominantly controlled via inducible changes
in the acetylation and deacetylation of histones, as opposed to
changes in the acetylation and deacetylation of transcription fac-
tors and their coregulators.
HDACs
Opposing the action of HATs, histone deacetylases, which are
divided into five classes—class I (HDAC1, HDAC2, HDAC3,
and HDAC8), class IIa (HDAC4, HDAC5, HDAC7, and HDAC9),
class IIb (HDAC6 and HDAC10), class III (sirtuins, discussed
above), and class IV (HDAC11)—are responsible for the removal
of acetyl moieties from histones and, as such, are considered
transcriptional corepressors. However, new findings suggest
that class I and II HDACs also deacetylate nonhistone targets30 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.and that this can have either an activating or repressive effect
on transcription depending on the transcription factor and/or
coregulator targeted. Furthermore, studies in several different
tissues have identified that these HDACs function as key meta-
bolic coregulators (reviewed by Mihaylova and Shaw, 2013).
Investigation of HDAC function in the heart has implicated
these proteins in the regulation of cardiac energy homeostasis.
HDAC1 and HDAC2 were shown to play important, but redun-
dant, roles in cardiac development and growth. Conditional dele-
tion of Hdac1 and Hdac2 in cardiomyocytes resulted in severe
cardiac defects and lethality shortly after birth, and a single
copy of either Hdac1 or Hdac2 was sufficient to sustain mice
through normal development (Montgomery et al., 2007). Similar
conditional deletion of Hdac3 induced cardiac hypertrophy and
reprogramming of cardiomyocytes (Montgomery et al., 2008).
Increased fatty acid uptake and oxidation were observed, as
well as myocardial lipid accumulation, which were attributed to
elevated PPARa activity. In a different study, postnatal deletion
of Hdac3 in both cardiac and skeletal muscle, via muscle crea-
tine kinase (MCK) promoter-driven Cre expression, revealed hy-
pertrophic cardiomyopathy and heart failure in mice on a HFD
(Sun et al., 2011). Decreased expression of genes involved in
fatty acid metabolism, the electron transport chain, and the
tricarboxylic acid (TCA) cycle was observed. Furthermore, phar-
macological inhibition of class I HDACs, using an apicidin deriv-
ative (API-D), protected against cardiac hypertrophy in response
to pressure overload, generated by thoracic aortic constriction
(Gallo et al., 2008). In contrast, cardiac stress caused severe car-
diac hypertrophy in mice deficient in class IIa Hdac5 and Hdac9
(Chang et al., 2004; Zhang et al., 2002). While these studies
highlight the metabolic roles of HDACs, they also unveil the
complexity underlying HDAC function in the heart.
The role of the class IIa HDACs in muscle physiology has been
well studied and provides a key example of these HDACs func-
tioning as coregulators that direct precise metabolic outcomes.
The class IIa HDACs are thought to play a suppressive role in
myogenesis and muscle fiber switching via specific repression
ofMEF2 familymembers (Kim et al., 2008; Lu et al., 2000;McKin-
sey et al., 2000a). MEF2s are believed to be key transcriptional
regulators for the oxidative, slow twitch (type I) myofibers.
Genetic deletion of multiple class IIa HDACs in skeletal muscle
promoted derepression of MEF2 target genes and the corre-
sponding metabolic reprogramming of glycolytic to oxidative
fibers (Potthoff et al., 2007). Furthermore, it has been suggested
that direct HDAC3-dependent deacetylation of MEF2 may be
another mode of MEF2 regulation in myogenesis (Gre´goire
et al., 2007). Considering that the class IIa HDACs themselves
bear minimal intrinsic deacetylase activity (Lahm et al., 2007;
Schuetz et al., 2008), and the deacetylase activity found associ-
ated with them in vivo has been attributed to their association
with HDAC3 (Fischle et al., 2001, 2002; Greco et al., 2011), it is
conceivable that recruitment of HDAC3 to MEF2 may contribute
to class IIa HDAC function in muscle (Nebbioso et al., 2009).
Importantly, the class IIa HDACs are often found in complex
with the HDAC3-NCoR1/SMRT complex (discussed above)
(Downes et al., 2000; Fischle et al., 2002; Guenther et al.,
2000; Huang et al., 2000; Kao et al., 2000; Li et al., 2000;
Yang and Seto, 2008; Yoon et al., 2003), and the interplay be-
tween the HDACs and this corepressor complex determines
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NCoR1skm/ mice display an increase in exercise endurance,
oxidative muscle metabolism, and mitochondrial quantity, which
can be attributed to the derepression of PPARb/PPARd, ERRs,
and MEF2 and linked to MEF2 hyperacetylation (Yamamoto
et al., 2011). An elegant dissection of a role for class IIa HDACs
in denervation-induced expression of the muscle-wasting-
inducing E3 ligases atrogin-1 and MuRF1 reveals that these
HDACs may also be controlling neurogenic muscle atrophy
(Moresi et al., 2010).
Important roles of HDAC3 and class IIa HDACs in liver meta-
bolism have also recently emerged. Conditional Hdac3 deletion
resulted in severe hepatic steatosis and elevated expression of
lipogenic enzymes (Feng et al., 2011; Knutson et al., 2008).
Furthermore, HDAC3 binding exhibited a circadian pattern,
which correlated inversely with histone acetylation (Feng et al.,
2011). Recruitment of HDAC3 to lipogenic gene loci required
the nuclear receptor Rev-Erba, a component of the circadian
clock machinery, to repress lipogenic gene expression during
the day (Figure 2C). Further metabolic phenotypes of Hdac3
deletion were also observed, including lower fasting blood
glucose and insulin levels (Knutson et al., 2008; Sun et al.,
2012). Although these studies underscore the importance of
HDAC3 in glucose and lipid metabolism, it is important to note
that many of the effects of HDAC3 on metabolism are indepen-
dent of its deacetylase activity (Sun et al., 2013).
Class IIa HDACs are also important in the control of hepatic
glucose metabolism. Class IIa Hdac knockdown resulted in
glycogen accumulation and decreased blood glucose in murine
models of the metabolic syndrome (Mihaylova et al., 2011).
Mechanistically, under fasted conditions or treatment with the
fasting hormone glucagon, class IIa HDACs induce the expres-
sion of gluconeogenic genes, including G6pc and Pck1, by re-
cruiting HDAC3 to deacetylate and activate the transcription
factor, FOXO1. Altogether, this study reveals that class IIa
HDAC-mediated deacetylation of a nuclear, nonhistone target,
FOXO1, mediates the translation of a hormonal signal into the
regulation of metabolic homeostasis.
Finally, pharmacological and genetic experiments suggest
that class I HDACs (HDAC1, HDAC2, and HDAC3) play roles in
adipocyte differentiation and may be therapeutic targets in dia-
betes and other metabolic diseases (Fajas et al., 2002b; Gal-
mozzi et al., 2013; Haberland et al., 2010). In the case of
HDAC3, the mechanism has been attributed to the inhibition of
PPARg by a complex of HDAC3 and the retinoblastoma protein
pRb (Fajas et al., 2002a). The role of class I and class IIa HDACs
in different metabolic tissues and the impact of HDAC inhibitors
of the metabolic function of different tissues in vivo are very
active areas of research.
CRTCs
Members of the cAMP-regulated transcriptional coactivator
(CRTC) protein family act as transcriptional coactivators of the
cyclic AMP-responsive element (CRE)-binding protein (CREB).
The family consists of CRTC1, CRTC2, and CRTC3. CRTC2,
the CRTC family member most enriched in the liver, has been
shown to regulate the CREB-dependent hepatic gluconeogenic
program (Koo et al., 2005; Saberi et al., 2009). Fasting and
glucagon treatment activate CRTC2, and fasting signals were
required for CRTC2-induced glucose production in hepatocytesand the induction of gluconeogenesis in vivo. Conversely, RNAi-
mediated reduction of Crtc2 in vivo resulted in fasting hypogly-
cemia (Koo et al., 2005), similar to that observed upon CREB
depletion by both targeted disruption and in vivo expression of
a dominant-negative CREB inhibitor (Herzig et al., 2001). These
observations were attributed in large part to CRTC2/CREB con-
trol of gluconeogenic gene expression, including that of Pepck1,
G6pc, and Ppargc1a (Herzig et al., 2001; Koo et al., 2005; Saberi
et al., 2009; Wang et al., 2010). As aberrant regulation of glucose
homeostasis is central to type 2 diabetes, the effects of Crtc2
knockdown in models of metabolic syndrome were assessed.
Depletion or knockout ofCrtc2 in mice fed aHFD reduced fasting
hepatic glucose production and hyperglycemia and improved in-
sulin sensitivity in both liver and skeletal muscle (Saberi et al.,
2009; Wang et al., 2010). Hyperglycemia was also improved in
Zucker diabetic fatty rats upon reduction of CRTC2. These re-
sults delineate the potential impact of CRTC coregulators in dia-
betes.
Mouse models have revealed that metabolic regulation by the
CRTCs extends to tissue contexts beyond the liver, including the
hypothalamus and adipose tissue. CRTC1 and CREB appear to
have a role in the hypothalamus, from which they coordinate
metabolic regulation in response to nutrient signals. CRTC1 is
predominantly expressed in the brain, yet Crtc1/ mice are
obese (Altarejos et al., 2008). These mice are hyperphagic,
display hypertriglyceridemia and hyperglycemia, and have
elevated circulating insulin and leptin levels. These metabolic
phenotypes were attributed to the misregulation of leptin
signaling in the hypothalamus of Crtc1/ mice due to direct
control of Cartpt and Kiss1, components of leptin signaling, by
CRTC1 and CREB.
Furthermore, Crtc3/ mice revealed that CRTC3 contributes
to catecholamine signaling in adipose tissue (Song et al., 2010).
Catecholamines are hormones produced by the sympathetic
nervous system and are recognized by adrenergic receptors.
Activation of adrenergic receptors stimulates the production of
cAMP, ultimately promoting lipolysis in WAT and fat burning in
BAT. Catecholamine signaling was found to activate CRTC3,
inducing the expression of the metabolic syndrome susceptibil-
ity gene, Rgs2, a direct CREB target. Crtc3/ adipocytes dis-
played increases in insulin and catecholamine signaling and,
correspondingly, enhanced glucose and fatty acid oxidation.
Systemically, Crtc3/ mice exhibited increased energy expen-
diture and resistance to diet-induced obesity. Notably, a human
CRTC3 variant associated with increased transcriptional activity
correlates with adiposity, linking CRTC3 function to obesity
(Song et al., 2010).
In keeping with the emerging role of the CRTCs as integrators
of systemic glucose handling, CRTC2 may also have important
metabolic functions in pancreatic b cells. CREB activity is
required for normal function of insulin-producing b cells of
pancreatic islets, as transgenic expression of dominant-nega-
tive A-Creb in b cells induced apoptosis and caused mice to
develop diabetes (Jhala et al., 2003). It has also been estab-
lished that cAMP and calcium signal through CRTC2 in pancre-
atic islet cells to affect the CREB-mediated response to nutrient
cues (Screaton et al., 2004). As such, in vivo studies are likely to
reveal important contributions of CRTC2 to CREB function in
this context.Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 31
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Figure 4. Molecular Model of Kinase-Mediated Control of CRTC2
and HDAC4/HDAC5/HDAC7 Subcellular Localization and Activity
The metabolic hormones glucagon and insulin signal through the glucagon
receptor (GR) and insulin receptor (IR), respectively, to initiate signaling
cascades downstream of changes in metabolic status. PKA and LKB1
phosphorylate (dark pink circles with a P) the AMPKRs (AMPK-related
kinases), including AMPK and SIK1/SIK2/SIK3, which, when active, phos-
phorylate CRTC2 and HDAC4/HDAC5/HDAC7, resulting in their cytoplasmic
sequestration. When unphosphorylated, CRTC2 and HDAC4/HDAC5/HDAC7
translocate to the nucleus (dashed lines), where they are free to promote the
activation of gluconeogenic gene expression programs through CREB and
the NCoR, HDAC3, FOXO complex, respectively. CRTC2 coactivates CREB,
and nuclear FOXO is activated upon HDAC4/HDAC5/HDAC7-mediated de-
acetylation (light pink circles). In parallel, AKT phosphorylation regulates the
activity of FOXO.
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The retinoblastoma protein (pRb) was identified as a tumor sup-
pressor that inhibits cell-cycle progression through inhibition of
the transcription factor E2F1. Upon phosphorylation by the
CDK/cyclin complex, pRb becomes unable to bind and inhibit
E2F1, thereby allowing cells to enter S phase. The functions of
pRb have since expanded to include roles ranging from cellular
differentiation to the control of whole-body metabolism. In fact,
pRb has a major impact on oxidative metabolism, through its
repressive actions on E2F1, which is a key regulator not only of
cell proliferation, but also of metabolism (Blanchet et al., 2011;
Fajas et al., 2002b, 2004). The absence of pRb hence favors
the development of more oxidative metabolic programs in BAT
(Calo et al., 2010; Dali-Youcef et al., 2007; Fajas et al., 2002a;
Scime` et al., 2005) and skeletal muscle (Blanchet et al., 2011),
as evidenced by studies in both cells and mouse models. This
makes pRb a very unique nodal point that directly connects
metabolism with cell proliferation and differentiation.
TRAP220/Mediator1
The mediator complex is a large multiprotein complex of coacti-
vators that forms a bridge between transcription factors and the
basal transcriptional machinery (Malik and Roeder, 2010). Sub-
unit 1 of this complex, Med1 (also known as TRAP220/
DRIP205/PBP), is important for adipocyte differentiation as it co-
activates PPARg and is required for enforced adipocyte differen-
tiation of MEFs (Ge et al., 2002). However, since Med1 links
many nuclear receptors (also including the thyroid hormone32 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.and vitamin D receptors) with the mediator complex, it remains
possible that the absence of Med1 has more promiscuous ef-
fects, depending on the interacting partner and the cellular
context. Indeed, specific aspects of constitutive androstane
receptor (CAR) and PPARa signaling, mainly related to genes
involved in peroxisome proliferation and hepatocellular regener-
ation, were attenuated in a mouse model with a liver-specific
Med1 inactivation (Jia et al., 2004; Matsumoto et al., 2007). Para-
doxically, and despite impaired hepatic PPARa signaling, these
mice are protected against HFD-induced hepatic steatosis,
due to impaired expression of PPARg-stimulated lipogenic
genes (Bai et al., 2011). A specific knockout of Med1 in skeletal
muscle improves insulin sensitivity and glucose tolerance and
results in resistance to diet-induced obesity (Chen et al., 2010).
These beneficial effects are accompanied by an increase inmito-
chondrial density and expression of genes specific to type I and
type IIA fibers in white muscle, suggesting a switch between
fast-to-slow fibers (Chen et al., 2010). In contrast, transcription
factors outside the nuclear receptor family do not seem to be
critically dependent on Med1 for contacting the mediator com-
plex, since MyoD-stimulated myogenesis is normal in Med1/
fibroblasts; however, additional transcription factors need to
examined (Ge et al., 2002).
Modulation of Coregulator Activity by Upstream
Signaling Pathways
Signaling Pathways
There are a number of metabolic signaling pathways that
converge on the coregulators under discussion to coordinate
their activity in response to nutritional and hormonal cues. In
particular, there are a limited number of serine/threonine kinases
that directly phosphorylate different subsets of these transcrip-
tional regulators, thus coordinating their activity to achieve spe-
cific metabolic adaptations following activation of signaling
pathway. Three kinases are particular notable: AKT, the central
kinase activated by insulin, plays key roles in glucose and lipid
homeostasis (Manning and Cantley, 2007); AMPK, activated un-
der conditions of low intracellular ATP following metabolic stress
or nutrient deprivation, as well as in reaction to adiponectin and
other metabolic cytokines (Canto´ and Auwerx, 2010; Hardie
et al., 2012; Mihaylova and Shaw, 2011); and the p38 family of
MAPKs, which are activated by oxidative stress and inflamma-
tory cytokines (Evans et al., 2002). As one could devote an exten-
sive review to any one of these regulatory modules, we will only
touch upon the mechanisms employed in the control of tran-
scriptional regulators.
Subcellular Compartmentalization and Nuclear
Translocation
Control of coregulator subcellular localization has been revealed
as a major regulatory mechanism utilized to mediate metabolic
outcomes. Here, we discuss two examples sharing a common
regulatory mechanism: the class IIa HDACs and the CRTCs
(Figure 4). Several studies have shown that class IIa HDACs
are regulated downstream of the CaMK, PKD, and AMPK kinase
families (Berdeaux et al., 2007; Kim et al., 2008; McGee et al.,
2008; McKinsey et al., 2000b; Mihaylova et al., 2011; Passier
et al., 2000; Vega et al., 2004; Walkinshaw et al., 2013). Upon
phosphorylation, the class IIa HDACs bind to 14-3-3 scaffold
proteins and are sequestered into the cytoplasm, where they
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shuttle to the nucleus, where they can play their regulatory role
in transcription (Grozinger and Schreiber, 2000; Kao et al.,
2001; McKinsey et al., 2000a; Wang et al., 2000). Indeed, several
studies have highlighted how the regulation of class IIa HDACs
through this mechanism contributes to control of physiology.
Phosphorylation of the class IIa HDACs by AMPK in myotubes
may be an upstream mechanism regulating HDAC-mediated
MEF2 control of GLUT4 expression andglucose uptake inmuscle
(McGee et al., 2008). Furthermore, fasting or treatment with the
fasting hormone glucagon leads to rapid dephosphorylation of
hepatic class IIa HDACs, resulting in their nuclear accumulation
(Mihaylova et al., 2011). Conversely, activation of AMPK induced
direct phosphorylation of class IIa HDACs and their exclu-
sion from the nucleus, ultimately suppressing FOXO-dependent
gluconeogenesis and glycogen storage. A study in Drosophila
found that insulin was able to induce the phosphorylation and
corresponding nuclear exclusion of class IIa HDACs by activating
the AMPK-related family member, salt-inducible kinase 3 (SIK3)
(Wang et al., 2011a). Depletion of dHDAC4, a class IIa HDAC,
reduceddFOXO-dependent control of fat-body lipaseexpression
initiating from dSIK3 deletion, suggesting an evolutionarily
conserved role for the class IIa HDACs asmediators of metabolic
hormonal signals downstream of AMPK-related kinases.
As with the class IIa HDACs, phosphorylation of hepatic
CRTC2 by SIKs and AMPK results in cytoplasmic sequestration
and association with 14-3-3 scaffold proteins (Koo et al., 2005;
Uebi et al., 2010) (Figure 4). In fasted conditions, attenuation of
AMPK and SIK1 activity results in dephosphorylation of CRTC2
at S171 and S307 (Koo et al., 2005; Uebi et al., 2010). Unphos-
phorylated hepatic CRTC2 is then free to translocate to the nu-
cleus, where it coactivates CREB to promote gluconeogenesis
by inducing gluconeogenic genes, including Pepck1, G6pc,
and Ppargc1 (Herzig et al., 2001; Koo et al., 2005; Saberi et al.,
2009). The CRTCs hence participate in a finely tuned system in
which phosphorylation states determine cellular shuttling and
protein activity in order to translate nutrient availability signals
into appropriately timed CREB-mediated glucose handling.
Interestingly, a mechanism to coordinate this phosphorylation
to the entrainment by the circadian clock was recently uncov-
ered when SIK1 was identified as a CREB-induced mRNA in
the light-entraining center of the brain, the suprachiasmatic
nuclei (Jagannath et al., 2013). The highly CREB-dependent na-
ture of the SIK1 promoter also provides a negative feedback
mechanism to enforce the inhibition of CRTC-dependent gene
expression (via SIK1 phosphorylation of CRTCs) as well as a
mechanism for CREB to crosstalk with other transcriptional pro-
grams via SIK1 phosphorylation and inhibition of class IIa HDACs
(Berdeaux et al., 2007).
Metabolites
An emerging theme is that metabolite availability can function as
an upstream signal to determine coregulator activity. For
example, the availability of acetyl coenzyme A (acetyl-CoA),
which acts as an acetyl donor for the acetyltransferases CBP/
p300, KAT2A, or NCoAs, may regulate the ability of these core-
gulators to acetylate their targets. There is, in fact, evidence of
biological fluctuations in intracellular levels of acetyl-CoA, sup-
porting the notion that this metabolite may function as a signal
of metabolic status whose levels could contain importantbiological information useful for directing coregulator activity
into relevant metabolic responses (Kaelin and McKnight, 2013).
However, most of the causal data are derived from budding
yeast, so an open question in the field is whether acetyl-CoA
levels are sufficiently dynamic in mammalian cells to allow
acetyl-CoA to act as a rate-limiting factor in some acetylation re-
actions. In budding yeast, it is clear that acetyl-CoA levels are
dynamically regulated and, in turn, dictate histone acetylation
and gene expression (Cai et al., 2011). In yeast, acetyl-CoA is
produced by two acetyl-CoA synthetases (Acs1p and Acs2p).
While Acs1p is localized within the mitochondria, Acs2p is a
cytoplasmic and nuclear protein. Acs2p is essential for histone
acetylation by HATs (Friis et al., 2009; Takahashi et al., 2006).
Indeed, high levels of nutrients drive the production of acetyl-
CoA through the activation of Acs2p, leading to histone acetyla-
tion via the stimulation of Gcn5p (Friis et al., 2009; van den Berg
et al., 1996). Whereas two acetyl-CoA synthases exist in mam-
mals, AceCS1 and AceCS2, their impact on nuclear acetyl-
CoA production is negligible. Mammals possess another
enzyme, ATP citrate lyase (ACLY), which is critical for cyto-
plasmic and nuclear production of acetyl-CoA (Wellen et al.,
2009). Acetyl-CoA produced by ACLY synchronizes information
about the cellular energy balance with histone acetylation
through KAT2A (Wellen et al., 2009). The regulation of KAT2A-
mediated histone acetylation by acetyl-CoA/ACLY suggests
that a similar mechanism may acetylate nonhistone proteins,
such as PGC-1a, in an energy-dependent manner. Further
studies are therefore warranted to explore the coupling between
metabolism and protein acetylation.
Not only acetyl-CoA levels, but also other metabolites, control
coregulator activity. We briefly discuss the role of NAD+ and hex-
osamine intermediates in the section below on integrated
signaling. Formore in-depth coverage of the role of thesemetab-
olites, we refer the readers to other recent reviews (Houtkooper
et al., 2010; Oosterveer and Schoonjans, 2014; Ruan et al.,
2013).
When solving the structure of HDAC3 in complex with the
SMRT deacetylase activating domain (DAD), the metabolite
inositol-(1,4,5,6)-tetraphosphate (Ins[1,4,5,6]P4) was discovered
as a key and essential component of this complex (Watson et al.,
2012). Together with inositol polyphosphate multikinase (IPMK),
the phosphatase and tensin homolog (PTEN) leads to the forma-
tion of Ins(1,4,5,6)P4, which acts as an adhesive molecule for the
SMRT/HDAC3 complex, enhancing the repressive activity of
these corepressors (Watson et al., 2012). This observation has
been expanded by demonstrating that Ins(1,4,5,6)P4 enhances
the activity of the HDAC3/SMRT complex as well as the
HDAC1/MTA1 complex (Millard et al., 2013). Furthermore, the
concentrations of Ins(1,4,5,6)P4 necessary to promote HDAC
complex formation are within the range found in cells (Millard
et al., 2013). Whether the levels of Ins(1,4,5,6)P4 fluctuate under
physiological circumstances remains to be established; how-
ever, there is evidence that such modulations can occur during
the cell cycle (Mattingly et al., 1991). Together, these studies
illustrate that a metabolite can function as a necessary structural
component of coregulator complexes, thus providing a different
mechanism through which metabolites can translate metabolic
regulatory signals into functional cellular responses via coregula-
tor proteins.Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc. 33
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pathways and metabolites also raises the possibility that these
features can be exploited within a therapeutic context. Certainly,
novel chemical entities or natural compounds can be identified
to mimic the impact of metabolites and signaling factors on
cofactor function. The fact that cofactors have pleiotropic effects
and can target multiple pathways poses a challenge for the
development of coregulator drugs, however. Furthermore, not
all coregulators may be equal when it comes to drug develop-
ment. Coregulators with an enzymatic activity, or an activity sub-
ject to control by signaling pathways or small molecules, may be
easier to target. On the other hand, the complexity of the regula-
tory circuit controlled by these coregulators also provides an
opportunity, as drugs can be developed that specifically target
some, but not all, pathways that are controlled by cofactors.
As a case in point, recent studies show that HDACs can have
an effect on transcriptional regulation that is independent of their
enzymatic activity as deacetylases (Sun et al., 2013). HDAC in-
hibitors, which are already undergoing advanced clinical testing
within the cancer field, may therefore have a different phenotypic
footprint than molecules that disrupt the interaction between
HDACs and NCoR1/SMRT by altering the quantity (or quality)
of Ins(1,4,5,6)P4 (Sun et al., 2013; Watson et al., 2012).
Coregulators as Energy Sensor Effectors: Integrated
Signaling
From the information above, it becomes clear that a yin-yang be-
tween corepressors and coactivators fine-tunes transcriptional
networks that control many aspects of metabolism. We will illus-
trate this through two exemplars. On the one hand, we will
discuss the interaction of corepressors (such as NCoR1 and
SIRT1) and coactivators (like PGC-1a, the NCoAs, and KAT2A/
KAT2B) to control muscle energy homeostasis; on the other
hand, we will discuss the interconnectivity of the CRTCs and
class IIa HDACs to control hepatic gluconeogenesis.
How the activity of various signaling pathways and coregula-
tors equilibrate energy harvesting pathways in the mitochondria
with cellular energy requirements illustrates this principle well.
During situations when energy supplies are limiting, such as dur-
ing caloric restriction (Canto´ et al., 2010; Chen et al., 2008) or
upon fasting and exercise (Canto´ et al., 2009, 2010), the cellular
ATP/AMP ratio will decrease and activate AMPK. This AMPK
activation is concomitant with a rise in cellular NAD+ levels,
which will activate SIRT1. The increase in the activity of AMPK
and SIRT1 will then activate PGC-1a (Canto´ et al., 2009; Ja¨ger
et al., 2007; Rodgers et al., 2005). Reduced energy levels will
also attenuate mTORC1 and insulin signaling, which will lead
to the inhibition of the repressive activity of NCoR1, which will
no longer oppose the transcriptional coactivation by PGC-1a
(Sengupta et al., 2010; Yamamoto et al., 2011). Whereas the
changes discussed above are occurring in a cell-autonomous
context, reduction of energy will, on an organismal level, trans-
late into increased glucagon signaling. Glucagon will activate
cAMP/PKA signaling and increase SIRT1 phosphorylation
(Gerhart-Hines et al., 2011) and SIRT1 gene expression (Noriega
et al., 2011), two effects that will reinforce the activity of these
cofactor pathways. Together, this shift in cofactor balance favors
transcriptional programs that will promote oxidative mitochon-
drial metabolism, thereby enhancing the use of stored energy34 Cell Metabolism 20, July 1, 2014 ª2014 Elsevier Inc.during caloric restriction, fasting, or exercise (Figure 3). Beyond
the strict physiological context, NAD+ levels can be increased
pharmacologically by administration of either NAD+ precursors,
such as nicotinamide riboside, or inhibitors of NAD+-consuming
enzymes, such as the PARP inhibitors (for review see
Houtkooper and Auwerx, 2012; Houtkooper et al., 2010).
These processes are reversed by situations of excessive en-
ergy intake, when the activity of AMPK and SIRT1 is attenuated
due to high intracellular ATP and low NAD+ levels. Calorie-dense
diets, furthermore, induce the expression of the acetyltrans-
ferases, NCoA3 and KAT2A, while concomitantly reducing
SIRT1 levels (Coste et al., 2008; Noriega et al., 2011). One result
is the acetylation and inhibition of PGC-1a, which in turn attenu-
ates mitochondrial activity. Furthermore, NCoR1 is activated by
insulin andmTORC1 signaling, accentuating the decreased tran-
scription of genes governing mitochondrial activity, ultimately
enabling the storage of excess calories in times of excessive
caloric intake.
The transcriptional control of gluconeogenesis in the liver by
coregulators is another case in point to illustrate the complexity
of coregulator signaling. Ten years ago, it was appreciated that
CREB and FOXO transcription factors are critical mediators of
the promoters of the core gluconeogenic enzymes Pepck and
G6pc, with CREB mediating positive effects from glucagon
and FOXO being suppressed by insulin-dependent signaling.
Onto that simple framework has now emerged the realization
that the CRTC family of CREB coactivators is shuttled into the
nucleus in response to glucagon and shuttled out in response
to insulin. Perfectly parallel to that are recent findings that the
class IIa family of HDACs promotes FOXO activation at these
gluconeogenic targets and is also shuttled into the nucleus
following glucagon and shuttled out following insulin (Figure 4).
It is striking that the functional activity of both the class IIa
HDACs and the CRTCs is regulated downstream of glucagon
signaling in an identical manner through a phosphorylation-
dependent mechanism involving 14-3-3 binding and cyto-
plasmic sequestration. In fact, of all of the transcription factors
and coregulators known as AMPK substrates, the class IIa
HDACs and the CRTCs are the only targets identified to date
that function in this manner.
In addition to the hormonal control by phosphorylation of
CRTCs, acetylation and ubiquitylation were shown to regulate
the temporal component of hepatic CRTC2 coregulatory func-
tion (Liu et al., 2008). CRTC2 protein stability is enhanced by
CBP/p300-mediated acetylation at K628 in response to
glucagon, promoting the induction of gluconeogenesis (Liu
et al., 2008; Ravnskjaer et al., 2007). Prolonged fasting, however,
induces SIRT1 via a PKA-dependent mechanism (Gerhart-Hines
et al., 2011; Noriega et al., 2011) and ultimately results in the de-
acetylation of CRTC2. Ubiquitylation and proteasome-depen-
dent degradation then follow, decreasing CRTC2 activity in order
to dampen the gluconeogenic program. Finally, CRTC2 can also
be O-glycosylated at S171 (Dentin et al., 2008), one of the sites
whose phosphorylation status determines CRTC2 cellular local-
ization. Indeed, CRTC2 O-glycosylation blocked phosphoryla-
tion at S171, resulting in its nuclear localization and enhanced
CREB activity. CRTC2 O-glycosylation was also linked to
elevated circulating glucose. Considering that elevated glucose
levels result in increased flux through the hexosamine
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tion, the O-glycosylation of CRTC2 provides an elegant example
of metabolic cues utilizing posttranslational modifications
(PTMs) to direct the activity of coregulatory proteins (Oosterveer
and Schoonjans, 2014).
The emergent complexity of these regulatory circuits hence
illustrates howmultifaceted transcriptional coregulator networks
convert signals not only associated with cellular energy status,
but also with organismal endocrine balance, into coherent and
coordinated changes of transcriptional activity, thereby modu-
lating whole-body metabolic homeostasis.
Future Perspectives
Coregulators are now recognized as central, evolutionarily
conserved players in metabolism. On top of regulation by tran-
scription factors, coregulators provide a second, more subtle,
global level of transcriptional metabolic adaptation. Although
an impressive body of work already implicates the PGC-1a
and sirtuin coregulators as central to many metabolic regulatory
networks, the work reviewed herein highlights the involvement of
other coregulators in metabolic homeostasis. Whereas most of
these studies addressed the role of coregulators in energy stor-
age and expenditure in muscle and fat and in hepatic glucose
and lipid metabolism, our knowledge on how they contribute to
the control of metabolic homeostasis in the CNS, pancreas,
and intestine is still incomplete. One emerging theme in many
tissues is that the final transcriptional output is determined by
a context-specific and dynamic balance between the opposing
actions of coactivators and corepressors.
It has also become clear that several coregulators are not only
transcriptional effectors, but also exquisitely sensitive metabolic
sensors that capture discrete changes in nutrient andmetabolite
availability and transform them into transcriptional responses,
much like ligand-activated transcription factors. A few examples
are as follows: (1) coregulator regulation through acetylation is
linked to the availability of metabolic intermediates such as
acetyl-CoA, which acts as an acetyl donor for acetyltransferases
such as CBP/p300, KAT2A, and NCoAs (Jeninga et al., 2010;
Wellen et al., 2009); (2) cellular NAD+ levels, which are tightly
regulated by the cellular energy balance, are likewise indispens-
able for the deacetylase activity of the sirtuins (Houtkooper et al.,
2010); (3) the activity of class I HDACs is inhibited by high
concentrations of hydroxyl butyrate, one of the ketone bodies
(Shimazu et al., 2013); and (4) the control of hexosamine/
O-glycosylation by elevated glucose levels (Dentin et al., 2008)
(reviewed by Oosterveer and Schoonjans, 2014).
Research that combines molecular, cellular, and pharmaco-
logical studies with gain- and loss-of-function genetic ap-
proaches in different model organisms should improve our
knowledge of how coregulators orchestratemetabolic networks.
Human genetic studies to link coregulators with metabolic phe-
notypes and diseases are also urgently required if we want to
validate coregulators as therapeutic targets, as has already
been done in the cancer field (Gryder et al., 2012). Another
research goal should be to elucidate the contribution of the
different transcription factors to the physiological actions of
coregulators. Defining the signaling pathways—second mes-
sengers, hormones, metabolites—that modulate the interaction
between transcription factors and coregulators is in that contexthighly relevant. This last line of investigation is of particular
importance with respect to the identification and development
of novel compounds that alter (increase or decrease) the affinity
between coregulators and transcription factors and direct the
activity of cofactors toward specific pathways or cells/tissues
(Feige and Auwerx, 2007; Rosenfeld et al., 2006).
If all of these goals are met, therapeutic targeting of transcrip-
tional nodes under coregulator control may become a reality in
the not too distant future. SIRT1 and PGC-1a are already prime
candidate targets. Several pathways interfering with SIRT1
activity, ranging from synthetic small molecule agonists to phar-
macological strategies that increase the levels of its natural co-
substrate, NAD+, are already in late-stage clinical testing and
are reviewed elsewhere (Canto´ and Auwerx, 2012; Houtkooper
and Auwerx, 2012). Also for PGC-1a, pharmacological interven-
tions that target its expression or activity or favor its selective
recruitment to specific transcription factors have been described
(see Andreux et al., 2013 for review). Dissections of the action of
HDAC inhibitors in metabolic tissues suggest that potential ther-
apeutic avenues may also exist for these coregulator targets
(Fajas et al., 2002a; Galmozzi et al., 2013), and the recent devel-
opment of new class II-specific HDAC inhibitors provides an
opportunity to examine their potential use in specific metabolic
disorders (Lobera et al., 2013). Recent high-throughput
screening efforts have also identified small molecule inhibitors
that directly bind NCoA1 and NCoA3 (Wang et al., 2011b). We
are furthermore hopeful that other coregulators will join the list
of potential metabolic targets in the near future.ACKNOWLEDGMENTS
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